Literature DB >> 3298467

Distinguishable pathways of viral antigen presentation to T lymphocytes.

L A Morrison, V L Braciale, T J Braciale.   

Abstract

Mesh:

Substances:

Year:  1986        PMID: 3298467     DOI: 10.1007/BF02935502

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


× No keyword cloud information.
  43 in total

1.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides.

Authors:  A R Townsend; J Rothbard; F M Gotch; G Bahadur; D Wraith; A J McMichael
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.

Authors:  S Ohkuma; B Poole
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

Review 3.  Functional and structural considerations in the recognition of virus-infected cells by cytotoxic T lymphocytes.

Authors:  T J Braciale; G L Ada; K L Yap
Journal:  Contemp Top Mol Immunol       Date:  1978

4.  Early presence of ribonucleoprotein antigen on surface of influenza virus-infected cells.

Authors:  J L Virelizier; A C Allison; J S Oxford; G C Schild
Journal:  Nature       Date:  1977-03-03       Impact factor: 49.962

5.  Antigen presentation: comments on its regulation and mechanism.

Authors:  E R Unanue; D I Beller; C Y Lu; P M Allen
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

6.  A viral polymerase involved in recognition of influenza virus-infected cells by a cytotoxic T-cell clone.

Authors:  J R Bennink; J W Yewdell; W Gerhard
Journal:  Nature       Date:  1982-03-04       Impact factor: 49.962

7.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Human cytotoxic T cell clones directed against herpes simplex virus-infected cells. I. Lysis restricted by HLA class II MB and DR antigens.

Authors:  M Yasukawa; J M Zarling
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

9.  Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens.

Authors:  S Jacobson; J R Richert; W E Biddison; A Satinsky; R J Hartzman; H F McFarland
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

10.  Expression of specific cytolytic activity by H-2I region-restricted, influenza virus-specific T lymphocyte clones.

Authors:  A E Lukacher; L A Morrison; V L Braciale; B Malissen; T J Braciale
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

View more
  5 in total

1.  Isolation and characterization of yeast artificial chromosome clones linking the HLA-B and HLA-C loci.

Authors:  S K Bronson; J Pei; P Taillon-Miller; M J Chorney; D E Geraghty; D D Chaplin
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

2.  Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides.

Authors:  M K Hart; K J Weinhold; R M Scearce; E M Washburn; C A Clark; T J Palker; B F Haynes
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

3.  A lung-specific neo-antigen elicits specific CD8+ T cell tolerance with preserved CD4+ T cell reactivity. Implications for immune-mediated lung disease.

Authors:  R I Enelow; M H Stoler; A Srikiatkhachorn; C Kerlakian; S Agersborg; J A Whitsett; T J Braciale
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

4.  Use of fixed autologous stimulator cells to correctly present human immunodeficiency virus type 1 viral peptides to nonhuman primate lymphocytes in proliferation and cytotoxic T-lymphocyte assays.

Authors:  K J Munroe; C A Anderson; J Y Wu; M S Wyand; G W Newman; M J Newman
Journal:  Clin Diagn Lab Immunol       Date:  1994-05

Review 5.  Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

Authors:  Eric A Meyerowitz; Augustin G L Vannier; Morgan G N Friesen; Sara Schoenfeld; Jeffrey A Gelfand; Michael V Callahan; Arthur Y Kim; Patrick M Reeves; Mark C Poznansky
Journal:  FASEB J       Date:  2020-04-29       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.